BMRN
Biomarin Pharmaceutical Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment
Market Cap: 16.4 Billion
Primary Exchange: NASDAQ
Website: http://www.bmrn.com/
Shares Outstanding: 189 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.7391100096927429
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 2549 trading days
From: 2015-07-20 To: 2024-03-07
Lowest Point:
BIIB Is For Buy-O-Gen
via: SeekingAlpha at 2019-06-12 06:30:36:000
Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc… read more...
BIIB Is For Buy-O-Gen
via: SeekingAlpha at 2019-06-12 06:30:36:000
Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2019 Update
via: SeekingAlpha at 2019-06-12 01:06:09:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Ole Andreas Halvorsen… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2019 Update
via: SeekingAlpha at 2019-06-12 01:06:09:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Ole Andreas Halvorsen… read more...
Week In Review: Frontage, A U.S.-China CRO, Stages $205 Million Hong Kong IPO
via: SeekingAlpha at 2019-06-10 00:47:20:000
Deals and Financings Frontage Holdings, a US-China CRO, raised $205 million in a Hong Kong IPO at a market capitalization of $820 million. It moved 4.5% higher on its first day of trading. According to Frontage, it will allocate 20% of the proceeds to meet increased demand, 40% for organic e… read more...
Week In Review: Frontage, A U.S.-China CRO, Stages $205 Million Hong Kong IPO
via: SeekingAlpha at 2019-06-10 00:47:20:000
Deals and Financings Frontage Holdings, a US-China CRO, raised $205 million in a Hong Kong IPO at a market capitalization of $820 million. It moved 4.5% higher on its first day of trading. According to Frontage, it will allocate 20% of the proceeds to meet increased demand, 40% for organic e… read more...
Chewy IPO, Lululemon And Tesla On Tap (Stocks To Watch Podcast)
via: SeekingAlpha at 2019-06-09 03:30:00:000
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks.. If you are interested in listening to Stocks To Watch to start your Sunday (you can r… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|